All In Biotech

NDA 204384 · Janssen Therap

Sirturo

Bedaquiline Fumarate · Oral

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 28, 2012

Approved uses

5

Original approval plus efficacy supplements

Registered trials

92

30 Phase 3, 15 recruiting

FAERS reports

1,441

1,379 serious, 341 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: QTc PROLONGATION QTc prolongation can occur with SIRTURO. Use with drugs that prolong the QTc interval may cause additive QTc prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or QTc interval greater than 500 ms develops [see Warnings and Precautions (5.1) ] . WARNING: QTc PROLONGATION See full prescribing information for complete boxed warning. QTc Prolongation QTc prolongation can occur with SIRTURO. Use with drugs that prolong the QTc interval may cause additive QTc prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or QTc interval greater than 500 ms develops. ( 5.1 )

What it is approved for

From the label in effect Oct 17, 2025.

SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. ( 1 ) Limitations of Use : Do not use SIRTURO for the treatment of latent, extra-pulmonary or drug-sensitive TB or for the treatment of infections caused by non-tuberculous mycobacteria. ( 1 ) Limitations of Use Do not use SIRTURO for the treatment of: Latent infection due to Mycobacterium tuberculosis ( M. tuberculosis ) Drug-sensitive pulmonary TB Extra-pulmonary TB Infections caused by non-tuberculous mycobacteria

Mechanism: Bedaquiline is a diarylquinoline antimycobacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SIRTURO · BEDAQUILINE FUMARATE EQ 100MG BASE · TABLET, ORAL · Prescription
  • SIRTURO · BEDAQUILINE FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bedaquiline" as an intervention, any sponsor and status, largest first.

All 92 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • electrocardiogram qt prolonged223
  • off label use174
  • hepatotoxicity149
  • anaemia146
  • neuropathy peripheral109
  • nausea93
  • death73
  • intentional product use issue72
  • vomiting72
  • decreased appetite46
  • dyspnoea46
  • dizziness44

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
201521
201632
201774
2018199
2019266
2020155
202177
2022193
2023145
2024119
2025102
202657

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sirturo (Bedaquiline Fumarate)

2024 spending

$2.8M

Beneficiaries

103

637 claims

Per beneficiary

$27,341

$159.10 per unit

View as table
YearSpending
2020$1,579,345
2021$2,041,547
2022$2,147,056
2023$3,019,486
2024$2,816,094

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 131 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.